|Official Full Name
|Recombinant Human Tumor Necrosis Factor-alpha/TNFSF2 (rHuTNF-alpha/TNFSF2)
|Amino Acid Sequence
|MVRSSSRTPS DKPVAHVVAN PQAEGQLQWL NRRANALLAN GVELRDNQLV VPSEGLYLIY SQVLFKGQGC PSTHVLLTHT ISRIAVSYQT KVNLLSAIKS PCQRETPEGA EAKPWYEPIY LGGVFQLEKG DRLSAEINRP DYLDFAESGQ VYFGIIAL
|Tumor Necrosis Factor, TNFSF2, Cachectin, Differentiation-inducing factor , DIF, Necrosin, Cytotoxin
|Tumor necrosis factor alpha (TNF-alpha), also called cachectin, is the best-know member of the TNF-family, which can cause cell death. This protein is produced by neutrophils, activated lymphocytes, macrophages, NK cells, LAK cells, astrocytes endothelial cells, smooth muscle cells and some transformed cells. TNF-alpha occurs as a secreted, soluble form and as a membrane-anchored form, both of which are biologically active. The naturally-occurring form of TNF-alpha is glycosylated, but non-glycosylated recombinant TNF-alpha has comparable biological activity. The biologically active native form of TNF-alpha is reportedly a trimer. Human and murine TNF-alpha show approximately 79 % homology at the amino acid level and cross-reactivity between the two species. Two types of receptors for TNF-alpha have been described and virtually all cell types studied show the presence of one or both of these receptor types.
|Approximately 17.5 kDa, a single non-glycosylated polypeptide chain containing 158 amino acids.
|Fully biologically active when compared to standard. The ED50 as determined by a cytotoxicity assay using murine L929 cells is less than 0.05 ng/ml, corresponding to a specific activity of > 2.0 × 107 IU/mg in the presence of actinomycin D.
|Sterile filtered white lyophilized (freeze-dried) powder.
|Lyophilized from a 0.2 um filtered concentrated solution in 20 mM PB, 10 mM Nacl, pH 7.0.
|Less than 1.0 EU/ug of rHuTNF-α/TNFSF2 as determined by LAL method.
|We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
|Stability and Storage
|Use a manual defrost freezer and avoid repeated freeze-thaw cycles.- 12 months from date of receipt, -20 to -70 °C as supplied.- 1 month, 2 to 8 °C under sterile conditions after reconstitution.- 3 months, -20 to -70 °C under sterile conditions after reconstitution.
|Safety Data Sheet (SDS) Download
|Click to download
|Technical Data Sheet (TDS) Download
|Click to download